ClinicalTrials.gg
Status unknownNCT03689881TOMOS SIUpdated Sep 27, 2019

Value of Tomosynthesis for the Detection of Sacro-iliitis (TOMOS SI)

An interventional study of Tomosynthesis of SI joints in Sacroiliitis, sponsored by University Hospital, Montpellier. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-27.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Sep 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Spondyloarthropathies (SpAs) are chronic inflammatory diseases encompassing ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthropathy, and undifferentiated SpA.

In 2001, the estimated prevalence of SpA was 1.5% worldwide. Sacroiliitis is a condition caused by inflammation within the sacroiliac joint. It is the most frequent damage of SpA depicted at imaging evaluation.

Conventional radiography (X-ray) is usually used to depict the structural changes associated with sacroiliitis.

However further evaluation often requires additionnal computed tomography (CT).

Tomosynthesis is an Xray-based imaging technology which allows reconstruction of multiple section images from a set of projection images acquired as the x-ray tube moves along a prescribed path. The advantagee of tomosynthesis is the significant reduction of radiation dose exposure compared to CT Tomosynthesis is currently used in the field of breast imaging and pneumology. Very few studies have examined the value of tomosynthesis for osteoarticular imaging.

The study aims at evaluating the diagnostic performances of tomosynthesis as compared to standard X-ray and CT, in patients with a clinical suspicion of sacroiliitis.

the investigators hypothesize that tomosynthesis is superior to conventional radiography for detection of sacroiliitis and is at least equal to CT with lower irradiation.

Read the detailed description

Consecutive patients referred to CT for exploration of sacrollitis will be included and investigated with standard radiography, CT and tomosynthesis of SI joints.

Imaging examinations will be performed at day of enrollment as follow : X-ray and CT as standard management and tomosynthesis as additional evaluation. CT will be considered as the reference standard Sacroiliitis will be assessed in a centralized, blind and randomized retrospective reading of all imaging modalities by two independent radiologists.

Diagnostic performances and radiation doses of tomosynthesis will be compared to those of standard CT and X-ray examinations.

02

Conditions studied

  • Sacroiliitis

Browse trials for

Keywords

  • Sacroiliitis
  • SI joint
  • tomosynthesis
  • CT
  • Xray
03

In context

Sacroiliitis

42 studies on the registry are indexed under Sacroiliitis; 11 are open to participants now.

This study's planned enrollment of 30 is below the median of 48 across 28 interventional studies indexed under Sacroiliitis.

Browse Sacroiliitis studies →

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,261 studies on the registry; 224 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 and over referred for suspected sacroiliitis.
  • Patients who have entered into their participation agreement by signing the form.
  • Patient affiliated to a social security scheme or beneficiary.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women.
  • Vulnerable people according.
  • Major people placed under guardianship or curatorship.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Tomosynthesis

    Tomosynthesis of SI joints

    Device: Tomosynthesis of SI joints

Interventions

  • DeviceTomosynthesis of SI joints

    All patients will undergo additional tomosynthesis performed per study protocol along with Xray and CT performed as part of standard imaging evaluation of sacroillitis. Tomosynthesis of SI joints will be performed on a digital Tomosynthesis system (PLATINUM dRF v2 DMS/APELEM), with a single acquisition followed by coronal image reconstruction.

06

What researchers measure

Primary outcomes

  1. Presence of bone erosions and other structural lesions of SI joints

    sacroiliitis will be assessed independently for each imaging modality according to the modified New York criteria

    Time frame: 1 day of enrollment

Secondary outcomes

  1. radiation dose

    Radiation dose will be measured for each imaging evaluation and calculated as the effective dose in millisievert (mSv).

    Time frame: 1 day of enrollment

  2. inter reader agreement for the evaluation of sacroiliitis at tomosynthesis

    Inter reader agreement will be measured at retrospective evaluation.

    Time frame: at the end of patients enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03689881
Collaborators
DMS Apelem, Thales, Digisens, Medecom, BPIfrance, European Regional Development Fund
Responsible party
Sponsor
First posted
Oct 1, 2018
Start date
Oct 4, 2018
Primary completion
Dec 31, 2019 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
Sep 27, 2019

Study contacts

Catherine Cyteval, MD, PhD
Contact
c-cyteval@chu-montpellier.fr
+ 33 4 67 33 81 78
Catherine Cyteval, MD, PhD
principal investigator · Montpellier University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion